ライフサイエンスコーパス: pneumococcal polysaccharide

1 r the responses to pertactin and serotype 6B pneumococcal polysaccharide.

2 Four of the antibodies cross-reacted with pneumococcal polysaccharide.

3 f IgM memory cells in the immune response to pneumococcal polysaccharides.

4 pendent Ag LPS, and type II T-independent Ag pneumococcal polysaccharides.

5 65 to 86 years of age) adults in response to pneumococcal polysaccharide 4 (PPS4) and PPS14.

6 cells responsible for the production of anti-pneumococcal polysaccharide Ab has been unclear.

7 pendent humoral immune responses to isolated pneumococcal polysaccharide Ags and highlight the potent

8 d uninfected control subjects with 23-valent pneumococcal polysaccharide and tetanus toxoid vaccines.

9 ride standards were used for quantitation of pneumococcal polysaccharides and conjugates with confirm

10 or tetanus diphtheria combination, 23-valent pneumococcal polysaccharide, and for all vaccines combin

11 Tetanus toxoid, pneumococcal polysaccharide, and KLH vaccines as well as

12 s formed on immunization with thyroglobulin, pneumococcal polysaccharide, and ssDNA-methylated BSA.

13 normal concentrations of antibodies against pneumococcal polysaccharides, and better renal function

14 ter, two sets of latex particles coated with pneumococcal polysaccharides, and serotype-specific anti

15 but not those of anti-tetanus toxoid or anti-pneumococcal polysaccharide antibodies, fell significant

16 e of all immunoglobulins, IgG subclasses and pneumococcal polysaccharide antibodies.

17 The pneumococcal polysaccharide antibody response was impair

18 ss may reflect immune paralysis due to large pneumococcal polysaccharide antigen loads and/or a poten

19 generated antigen-specific IgM responses to pneumococcal polysaccharide antigens, whereas PC1(hi) ce

20 nce typing and a microarray for detection of pneumococcal polysaccharide capsule biosynthesis genes t

21 Levels of natural antibodies to the pneumococcal polysaccharide component phosphocholine wer

22 100 serotypes were initially included in the pneumococcal polysaccharide conjugate vaccine (PCV) in 2

23 The recent development of pneumococcal polysaccharide conjugate vaccines has led t

24 Pneumococcal polysaccharide conjugate vaccines prevent p

25 ococcal vaccine in the elderly, we evaluated pneumococcal polysaccharide-derived oligosaccharides con

26 ependent type 2 antigens (TI-2 Ags), such as pneumococcal polysaccharides, elicit weak immunoglobulin

27 ed IgG Ab production after immunization with pneumococcal polysaccharides in mice with disruptions in

28 nd immune response in neonatal mice, using a pneumococcal polysaccharide of serotype 1 conjugated to

29 However, TI-2 Ags, including pneumococcal polysaccharides, often elicit weak immunogl

30 fection or intraperitoneal immunization with pneumococcal polysaccharide or 4-hydroxy-3-nitrophenyl-a

31 Conjugation of various serotypes of pneumococcal polysaccharide (PnPS) to carrier protein en

32 hat respond to vaccination with the purified pneumococcal polysaccharide (PPS) has been a topic of de

33 By contrast, pneumococcal polysaccharide (PPS) immunization protected

34 Previous studies indicate that Abs to pneumococcal polysaccharide (PPS) serotypes 1 and 6B hav

35 Remarkably, pneumococcal polysaccharide (PPS) vaccination alone indu

36 The current pneumococcal polysaccharide (PPS) vaccine is highly effe

37 viduals that respond poorly to the 23-valent pneumococcal polysaccharide (PPS) vaccine, Pneumovax, su

38 In mice, pneumococcal polysaccharide (PPS) vaccines generate anti

39 fference in levels of IgG antibodies against pneumococcal polysaccharide (PPS), older adults had lowe

40 sed combinatorial library cloning to isolate pneumococcal polysaccharide (PPS)-specific Fab fragments

41 onse to T cell-independent (TI) Ags, such as pneumococcal polysaccharide (PPS).

42 her mice were naive or immunized with native pneumococcal polysaccharide (PPS; Pneumovax23) or protei

43 independent Ig isotype responses to isolated pneumococcal polysaccharides (PPS) required TLR signalin

44 ected persons to respond to vaccination with pneumococcal polysaccharides (PPS).

45 ine (T-dependent) and Pneumovax23 (23-valent pneumococcal polysaccharide [PPV23], T-independent).

46 ide comparable results for a large number of pneumococcal polysaccharide preparations.

47 The pneumococcal polysaccharide-protein conjugate vaccine-13

48 Pneumococcal polysaccharide-protein conjugate vaccines e

49 It is not known whether pneumococcal polysaccharide-protein conjugated vaccines

50 Widespread use of conjugate pneumococcal polysaccharide-protein vaccines may alter t

51 CD40 monoclonal antibody to mice, along with pneumococcal polysaccharide, provides a substitute for T

52 hreat to the success of vaccines that target pneumococcal polysaccharide (PS) capsule.

53 The type II T-independent Ag pneumococcal polysaccharide response was enhanced approx

54 have a receptor that interacts with capsular pneumococcal polysaccharides, setting the stage for furt

55 enabled even greater boosting of protective pneumococcal polysaccharide-specific IgG responses when

56 lly, late recovering patients displayed less pneumococcal polysaccharide-specific immunoglobin M-prod

57 neumococcus cells are impaired in generating pneumococcal polysaccharide-specific responses and succu

58 ore they had developed antibody responses to pneumococcal polysaccharide, still failed to show a resp

59 GBS-III, biochemically identical to capsular pneumococcal polysaccharide type 14 (PPS14) of Streptoco

60 detailed antibody responses after 23-valent pneumococcal polysaccharide vaccination (23vPPV).

61 sis of human observational data suggest that pneumococcal polysaccharide vaccination (PPV) could be p

62 Pneumococcal polysaccharide vaccination compared with no

63 Previous pneumococcal polysaccharide vaccination did not protect

64 23-valent pneumococcal polysaccharide vaccination is ineffective i

65 in antigens were normal, but the response to pneumococcal polysaccharide vaccination was moderately i

66 rs are considering such a recommendation for pneumococcal polysaccharide vaccination.

67 A 23-valent unconjugated pneumococcal polysaccharide vaccine (23vP), routinely ad

68 7; Prevnar) in infancy followed by 23-valent pneumococcal polysaccharide vaccine (23vPPV; Pneumovax)

69 -treated patients had decreased responses to pneumococcal polysaccharide vaccine (57% of patients had

70 rted that the 7-valent diphtheria-conjugated pneumococcal polysaccharide vaccine (PCV7) is safe and i

71 administration of the heptavalent conjugated pneumococcal polysaccharide vaccine (PCV7) were also ass

72 We compared revaccination with 23-valent pneumococcal polysaccharide vaccine (PN23) with primary

73 vaccination or revaccination with 23-valent pneumococcal polysaccharide vaccine (PN23).

74 ther passive immunization with the 23-valent pneumococcal polysaccharide vaccine (Pneumovax(R) 23; PP

75 The 23-valent pneumococcal polysaccharide vaccine (Pneumovax) might pr

76 All received 23-valent pneumococcal polysaccharide vaccine (PPS).

77 dose 6 months later, and 1 dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) 1 month lat

78 jugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) 2 months la

79 15-valent PCV (PCV15) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) 8 weeks lat

80 gate vaccine (PCV13) compared with 23-valent pneumococcal polysaccharide vaccine (PPSV23) among US ad

81 ortions and incidence matching the 23-valent pneumococcal polysaccharide vaccine (PPSV23) and 13-vale

82 usly vaccinated with >/= 1 dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) and had CD4

83 rt 1 (n = 350) previously received 23-valent pneumococcal polysaccharide vaccine (PPSV23) and were ra

84 tion Practices has recommended the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for nonelde

85 PD), with the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for prevent

86 Although the 23-valent pneumococcal polysaccharide vaccine (PPSV23) protects ag

87 te vaccine (PCV13) followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) remains unc

88 Controversy persists over the benefits of pneumococcal polysaccharide vaccine (PPV) for adults at

89 Revaccination of healthy adults with pneumococcal polysaccharide vaccine (PPV) within several

90 The 23-valent pneumococcal polysaccharide vaccine (PPV-23) uptake amon

91 Twenty-three-valent pneumococcal polysaccharide vaccine (PPV-23), which cont

92 (PCV13) concurrently, followed by 23-valent pneumococcal polysaccharide vaccine (PPV23) 2 months lat

93 determine the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) among Navajo

94 The benefits of using the 23-valent pneumococcal polysaccharide vaccine (PPV23) are controve

95 grouped serotypes contained in the 23-valent pneumococcal polysaccharide vaccine (PPV23) decreased at

96 Vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV23) is available

97 Since the 23-valent pneumococcal polysaccharide vaccine (PPV23) is less effe

98 In the United Kingdom, the 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommend

99 >/= 200 randomized to receive the 23-valent pneumococcal polysaccharide vaccine (PPV23) or placebo a

100 V (PCV13) vs regions that used the 23-valent pneumococcal polysaccharide vaccine (PPV23) was also ana

101 65 years or older; previously only 23-valent pneumococcal polysaccharide vaccine (PPV23) was recommen

102 and are indications for receipt of 23-valent pneumococcal polysaccharide vaccine (PPV23).

103 umonia (n = 16) and healthy volunteers given pneumococcal polysaccharide vaccine (PPV; n = 14) or pne

104 (PCV) followed by either a dose of 23-valent pneumococcal polysaccharide vaccine (PSV23) or a fourth

105 licensed (23-valent, 25 microgram/serotype) pneumococcal polysaccharide vaccine (PV).

106 lent conjugate vaccine [PCV13] and 23-valent pneumococcal polysaccharide vaccine [PPSV23]).

107 althy human adults with Pneumovax (23-valent pneumococcal polysaccharide vaccine [PPV23]), IgG anti-c

108 s, but it remains unclear whether use of the pneumococcal polysaccharide vaccine alters the overall r

109 697 received 23-valent pneumococcal polysaccharide vaccine and 695 received pla

110 The patient had received 23-valent pneumococcal polysaccharide vaccine and there was no evi

111 All children received 23-valent pneumococcal polysaccharide vaccine at age 13 months.

112 Four of 16 patients in group 1 responded to pneumococcal polysaccharide vaccine compared with 14 of

113 Immunization with the pneumococcal polysaccharide vaccine does not prevent col

114 The pneumococcal polysaccharide vaccine elicited comparable

115 se findings support the effectiveness of the pneumococcal polysaccharide vaccine for the prevention o

116 Pneumococcal polysaccharide vaccine is recommended for e

117 However, the effect of pneumococcal polysaccharide vaccine on vascular events r

118 e vaccine (PCV) followed by either a dose of pneumococcal polysaccharide vaccine or a fourth PCV dose

119 gate vaccine followed by 1 dose of 23-valent pneumococcal polysaccharide vaccine or a single dose of

120 udy murine immune responses to the 23-valent pneumococcal polysaccharide vaccine Pnu-Imune, both in v

121 e vaccine serotypes and 82.8% with 23-valent pneumococcal polysaccharide vaccine serotypes.

122 The 23-valent pneumococcal polysaccharide vaccine was formulated to pr

123 rs after transplantation and the response to pneumococcal polysaccharide vaccine was significantly lo

124 eritoneal B1b compartment, immunization with pneumococcal polysaccharide vaccine yielded comparable a

125 stem activation using the standard 23-valent pneumococcal polysaccharide vaccine, (3) daily sampling

126 rgeting high-risk groups was undertaken with pneumococcal polysaccharide vaccine, and subsequently ra

127 sera of people immunized with the 23-valent pneumococcal polysaccharide vaccine, we confirmed that h

128 ne response to that induced by the 23-valent pneumococcal polysaccharide vaccine, which has been the

129 were serotypes represented in the 23-valent pneumococcal polysaccharide vaccine.

130 lysaccharides used to formulate a polyvalent pneumococcal polysaccharide vaccine.

131 ates were serotypes that are included in the pneumococcal polysaccharide vaccine.

132 9F, and 23F linked to CRM197, or a 23-valent pneumococcal polysaccharide vaccine.

133 f dementia compared to the control 23-valent pneumococcal polysaccharide vaccine.

134 polysaccharide antigens was assessed using a pneumococcal polysaccharide vaccine.

135 pneumonia following receipt of the 23-valent pneumococcal polysaccharide vaccine.

136 with the conjugate vaccine compared with the pneumococcal polysaccharide vaccine.

137 re due to serotypes covered by the 23-valent pneumococcal polysaccharide vaccine.

138 uded in the 7-valent conjugate and 23-valent pneumococcal polysaccharide vaccines accounted for 78 pe

139 the influence of Km and Gm allotype genes on pneumococcal polysaccharide vaccines.

140 ons manifest decreased antibody responses to pneumococcal polysaccharide vaccines.

141 long-lasting, impaired antibody responses to pneumococcal polysaccharide vaccines.

142 of the UAD-2 assay was achieved by capturing pneumococcal polysaccharides with serotype-specific mono